LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

50.48 2.37

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.43

Max

50.52

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 51.415
EPS	0.208
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+27.95% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	65M 2.9B
Iepriekšējā atvēršanas cena	48.11
Iepriekšējā slēgšanas cena	50.48

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 22:50 UTC

Peļņas

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026. g. 12. maijs 22:49 UTC

Peļņas

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026. g. 12. maijs 22:32 UTC

Peļņas

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026. g. 12. maijs 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 12. maijs 22:57 UTC

Tirgus saruna

Peļņas

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026. g. 12. maijs 22:26 UTC

Peļņas

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure Interim Dividend A$0.50/Security

2026. g. 12. maijs 22:24 UTC

Peļņas

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026. g. 12. maijs 22:19 UTC

Peļņas

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026. g. 12. maijs 22:13 UTC

Peļņas

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026. g. 12. maijs 22:11 UTC

Peļņas

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026. g. 12. maijs 22:11 UTC

Peļņas

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026. g. 12. maijs 22:10 UTC

Peļņas

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026. g. 12. maijs 22:08 UTC

Peļņas

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026. g. 12. maijs 22:07 UTC

Peļņas

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026. g. 12. maijs 22:05 UTC

Peļņas

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

27.95% augšup

Prognoze 12 mēnešiem

Vidējais 63.17 USD 27.95%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.